



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

11th July 2025

The Manager-Listing
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

The Manager- Listing
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra-Kurla Complex
Bandra (E)
Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Sub - Outcome of Board Meeting.

Ref – Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements).

We inform you that the Board of Directors of the Company, at its Meeting held today i.e. on Friday 11th July 2025, has approved the Standalone and Consolidated unaudited financial results, for the quarter ended 30th June, 2025.

Pursuant to above-referred regulations, we enclose the following documents.

1. Statement of unaudited Standalone financial results, for the quarter ended 30th June 2025. (Annexure-I).
2. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results. (Annexure-II).
3. Statement of unaudited Consolidated financial results, for the quarter ended 30th June 2025. (Annexure-III).
4. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results. (Annexure-IV).
5. Appointment of Ms. Payal Jain as Independent Director of the Company.

Based on the recommendation of Nomination and remuneration committee and subject to approval of the shareholders and any regulatory approvals and applicable condition thereof, the board of Directors at its meeting held today on 11th July 2025, considered and approved the appointment of Ms. Payal Jain (DIN- 09272201) as Additional Director (to be appointed as Independent Director subject to approval of shareholders in AGM) of the Company) with immediate effect.

Details as required under SEBI master circular dated November 11, 2024 are enclosed as Annexure (Annexure-V).

The Meeting Commenced on 02:00 p.m. and concluded on 04:30 p.m.

The above information will be made available on the Company's website
www.nathbiogenes.com.

You are requested to take the above information on record.

Thanking You.

Yours faithfully,
For Nath Bio-Genes (India) Limited,

Amol Gupta
Chief Financial Officer

■ Nath House, Nath Road, Aurangabad - 431005 (MS) Tel : 0240-2376314/5/6/7
Email : info@nathseeds.com www.nathbiogenes.com

■ 1, Chateau Windsor, 86 Veer Nariman Road, Mumbai - 400020 (MS) Tel : 022-22871001, 22875653/4/5

NATH
GROUP



Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND 3 MONTHS ENDED 30/06/2025

Rs in Lakhs

SR. No.	Particulars	Quarter Ended			Three Months Ended		Year Ended
		30-06-2025 Unaudited	31-03-2025 Audited	30-06-2024 Unaudited	30-06-2025 Unaudited	30-06-2024 Unaudited	31-03-2025 Audited
I	Income from operations						
	(a) Revenue from operations	28017.18	4936.76	24387.51	28017.18	24387.51	36230.81
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income	28017.18	4936.76	24387.51	28017.18	24387.51	36230.81
II	Expenses						
	a) Production & Seed Conditioning Expenses	10824.23	10061.98	6267.39	10824.23	6267.39	21754.92
	b) Purchase of Stock-in-Trade	435.33	86.05	268.74	435.33	268.74	1250.82
	c) Change in Inventories of Produced and Traded Goods	2379.62	(8594.86)	5755.37	2379.62	5755.37	(9665.64)
	d) Employee Benefit Expense	905.17	550.80	637.45	905.17	637.45	3030.88
	e) Depreciation & Amortisation Expenses	97.50	131.55	82.50	97.50	82.50	379.05
	f) Selling & Distribution Expenses	8669.91	885.01	7002.47	8669.91	7002.47	11658.92
	g) Other Expenses	912.69	1631.29	750.22	912.69	750.22	2971.50
	Total Expenses	24224.44	4751.82	20764.16	24224.44	20764.16	31380.45
III	Profit from Operations before other income, finance cost and Exceptional Items (I-II)	3792.74	184.94	3623.36	3792.74	3623.36	4850.36
IV	Other Income	176.45	404.31	13.94	176.45	13.94	472.70
V	Profit from Ordinary Activities before Finance cost and Exceptional Items (III+IV)	3969.19	589.25	3637.30	3969.19	3637.30	5323.06
VI	Finance Cost	288.96	109.65	224.07	288.96	224.07	964.61
VII	Profit from Ordinary Activities after Finance cost (V-VI)	3680.23	479.60	3413.22	3680.23	3413.22	4358.45
VIII	Exceptional Items Income/(Expenses)	0.00	0.00	0.00	0.00	0.00	0.00
IX	Profit from Ordinary Activities before Tax (VII-VIII)	3680.23	479.60	3413.22	3680.23	3413.22	4358.45
X	Tax Expense						
	(a) Current Tax	65.97	59.97	24.53	65.97	24.53	203.70
	(b) Earlier Year Tax	0.00	2.76	0.00	0.00	0.00	(5.23)
	(c) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
XI	Net Profit from Ordinary Activities after Tax (IX-X)	3614.26	416.87	3388.70	3614.26	3388.70	4159.98
XII	Extra Ordinary Items (Net of Tax)	206.34	54.03	0.00	206.34	0.00	54.03
XIII	Net Profit for the period (XI-XII)	3820.60	470.90	3388.70	3820.60	3388.70	4214.01
XIV	Other Comprehensive Income						
	1. (a) Items that will not be reclassified to Profit or Loss	(1.50)	(41.64)	(12.42)	(1.50)	(12.42)	(6.57)
	(b) Income tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	2. (a) Items that will be reclassified to Profit or Loss	(6.50)	(26.47)	0.00	(6.50)	0.00	(26.47)
	(b) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	Total other Comprehensive Income	(8.00)	(68.11)	(12.42)	(8.00)	(12.42)	(33.04)
XV	Total Comprehensive Income for the period (XIII + XIV)	3812.60	402.79	3376.28	3812.60	3376.28	4180.97
XVI	Paid Up Equity Share Capital (Face Value Rs. 10/- each)	1900.40	1900.40	1900.40	1900.40	1900.40	1900.40
XVII	Reserve & Surplus						62966.30
XVIII	Earning per share (of Rs 10/- each) (not annualised) Basic & Diluted	20.06	2.12	17.77	20.06	17.77	22.00

NOTES:

- The standalone financial results were reviewed by the Audit Committee in meeting held on 10 July 2025 and were thereafter approved by the Board of Directors at its meeting held on 11 July 2025
- The company is dealing in one major product segment, i.e. Seed Cultivation.
- Investor complaints - Opening Balance - 0, Received and Solved - 0, Closing Balance - 0
- The figures have been regrouped/rearranged where ever necessary.


Place : Chhatrapati Sambhajnagar
Date : 11 July 2025



GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS
Gautam
GAUTAM NANDAWAT
(Partner)

FOR NATH BIO-GENES (INDIA) LTD

Satish
SATISH KAGLIWAL
MANAGING DIRECTOR
DIN 00119601



Regd. Office : Nath House, Nath Road, Chhatrapati Sambhajnagar - 431005 (MS)
www.nathbiogenes.com

UAIN: 25032742BMJJKS780



Gautam N Associates

Chartered Accountants

30, GNA House, Behind ABC Complex,
Manmandir Travels Lane, Adalat Road, Aurangabad - 431 001

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND YEAR TO DATE UNAUDITED STANDALONE IND-AS FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATION 2015, AS AMENDED

To,
The Board of Directors
Nath Bio-Genes (India) Limited
Chhatrapati Sambhajinagar

1. We have reviewed the accompanying standalone statement of unaudited financial results of **Nath Bio-Genes (India) Limited** for the quarter ended 30th June 2025 and year to date results for the period 1st April 2025 to 30th June 2025 ('The Statement') being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as modified.
2. This standalone statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.
3. We conducted our review of the standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the standalone financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying standalone statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gautam N Associates
Chartered Accountants
FRN: 103117W


Gautam Nandawat
Partner

M No: 032742

UDIN: **25032742BMJMK5780**

Place: Chhatrapati Sambhajinagar

Date: 11th July, 2025





Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND 3 MONTHS ENDED 30/06/2025

Rs in Lakhs

SR. No.	Particulars	Quarter Ended			Three Months Ended		Year Ended
		30-06-2025 Unaudited	31-03-2025 Audited	30-06-2024 Unaudited	30-06-2025 Unaudited	30-06-2024 Unaudited	31-03-2025 Audited
I	Income from operations						
	(a) Revenue from operations	28370.01	5196.77	24387.51	28370.01	24387.51	36490.82
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income	28370.01	5196.77	24387.51	28370.01	24387.51	36490.82
II	Expenses						
	a) Production & Seed Conditioning Expenses	10885.18	10159.91	6638.82	10885.18	6638.82	22553.84
	b) Purchase of Stock-in-Trade	435.33	95.30	282.15	435.33	282.15	1273.48
	c) Change in Inventories of Produced and Traded Goods	2661.88	(8487.36)	5370.53	2661.88	5370.53	(10272.54)
	d) Employee Benefit Expense	959.27	634.15	673.90	959.27	673.90	3250.38
	e) Depreciation & Amortisation Expenses	97.50	134.11	82.50	97.50	82.50	381.61
	f) Selling & Distribution Expenses	8669.91	1123.26	7002.47	8669.91	7002.47	11697.17
	g) Other Expenses	930.05	1630.20	766.06	930.05	766.06	3008.66
	Total Expenses	24639.12	5289.57	20816.45	24639.12	20816.45	31892.60
III	Profit from Operations before other income, finance cost and Exceptional Items (I-II)	3730.89	(92.80)	3571.07	3730.89	3571.07	4598.22
IV	Other Income	176.45	386.19	13.02	176.45	13.02	454.58
V	Profit from Ordinary Activities before Finance cost and Exceptional Items (III+IV)	3907.34	293.39	3584.09	3907.34	3584.09	5052.80
VI	Finance Cost	319.61	136.59	224.07	319.61	224.07	1048.38
VII	Profit from Ordinary Activities after Finance cost (V-VI)	3587.74	156.80	3360.02	3587.74	3360.02	4004.42
VIII	Exceptional Items Income/(Expenses)	0.00	0.00	0.00	0.00	0.00	0.00
IX	Profit from Ordinary Activities before Tax (VII-VIII)	3587.74	156.80	3360.02	3587.74	3360.02	4004.42
X	Tax Expense						
	(a) Current Tax	65.97	59.97	24.53	65.97	24.53	203.70
	(b) Earlier Year Tax	0.00	2.76	0.00	0.00	0.00	(5.23)
	(c) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
XI	Net Profit from Ordinary Activities after Tax (IX-X)	3521.77	94.07	3335.49	3521.77	3335.49	3805.95
XII	Extra Ordinary Items (Net of Tax)	206.34	54.03	0.00	206.34	0.00	54.03
XIII	Net Profit for the period (XI-XII)	3728.11	148.10	3335.49	3728.11	3335.49	3859.98
XIV	Other Comprehensive Income						
	1. (a) Items that will not be reclassified to Profit or Loss	(1.50)	(41.65)	(12.42)	(1.50)	(12.42)	(6.58)
	(b) Income tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	2. (a) Items that will be reclassified to Profit or Loss	(6.50)	(26.47)	0.00	(6.50)	0.00	(26.47)
	(b) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	Total other Comprehensive Income	(8.00)	(68.12)	(12.42)	(8.00)	(12.42)	(33.05)
XV	Total Comprehensive Income for the period (VII + VIII)	3720.11	79.98	3323.07	3720.11	3323.07	3826.93
XVI	Share in Profit / (Loss) of minority share holder	0.00	0.00	0.00	0.00	0.00	0.00
XVII	Profit related to Holding Company	3720.11	79.98	3323.07	3720.11	3323.07	3826.93
XVI	Paid Up Equity Share Capital (Face Value Rs. 10/- each)	1900.40	1900.40	1900.40	1900.40	1900.40	1900.40
XVII	Reserve & Surplus						62538.32
XVI	Earning per share (of Rs 10/- each) (not annualised) Basic & Diluted	19.58	0.42	17.49	19.58	17.49	20.14

NOTES:


- The consolidated financial results were reviewed by the Audit Committee in meeting held on 10 July 2025 and were thereafter approved by the Board of Directors at its meeting held on 11 July 2025.
- The company is dealing in one major product segment, i.e. Seed Cultivation.
- The results have been consolidated with Nath Bio-Genes CA, Uzbekistan, where in the company is holding 90% of equity.
- Investor complaints - Opening Balance - 0, Received and Solved - 0, Closing Balance - 0
- The figures have been regrouped/rearranged where ever necessary.



GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS
GAUTAM NAWAWAT
 (Partner)

FOR NATH BIO-GENES (INDIA) LTD.

Satish Kagliwal
SATISH KAGLIWAL
 MANAGING DIRECTOR
 DIN 00119601



Place : Chhatrapati Sambhajnagar

Date : 11 July 2025

Regd. Office : Nath House, Nath Road, Chhatrapati Sambhajnagar - 431005 (MS)
 www.nathbiogenes.com

UIN:- 25032742BFWJNL3309



Gautam N Associates Chartered Accountants

30, GNA House, Behind ABC Complex,
Manmandir Travels Lane, Adalat Road, Aurangabad - 431 001

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND YEAR TO DATE UNAUDITED CONSOLIDATED IND-AS FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATION 2015, AS AMENDED

To,
The Board of Directors
Nath Bio-Genes (India) Limited
Chhatrapati Sambhajinagar.

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Nath Bio-Genes (India) Limited** ("the company" or "Holding Company"), and its joint venture company ("the Holding Company and its joint venture company together referred to as 'the Group'"), for the quarter ended 30th June 2025 and year to date results for the period 1st April 2025 to 30th June 2025 ('The Statement') being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as modified.

A Joint Venture Entity is located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries. We have considered the unaudited quarterly financial results as authenticated by its management for the purpose of consolidation. The Holding Company's management has converted the financial results of such joint venture located outside India from accounting principles generally accepted in their respective country to accounting principles generally accepted in India (Ind AS). We have reviewed these conversion adjustments made by the Holding Company's management.

2. This consolidated statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act., 2013 read with relevant rules issued there under and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on this consolidated financial statement based on our review.
3. We conducted our review of the consolidated Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gautam N Associates
Chartered Accountants
FRN: 103117W


Gautam Nandawat
Partner
M No: 032742
UDIN: **25032742BMJJML3309**



Place: Chhatrapati Sambhajinagar
Date: 11th July, 2025



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

Details as required under SEBI master circular dated November 11, 2024 are enclosed as (Annexure-V)

Appointment of Ms. Payal Jain as Additional Director (Independent Director) of the Company.

Name of Director	Ms. Payal Jain
DIN	09272201
Designation	Additional Director (Independent)
Reason for Change (appointment)	Appointment of Ms. Payal Jain as Additional Director (Independent Director) of the Company. Subject to approval of Shareholders in the ensuing annual general meeting of the Company.
Date of Appointment	With effect from 11 th July 2025.
Brief Profile	<p>Ms. Payal is Company Secretary by profession, Accomplished 15+ years of professional experience with 5 years of real estate Professional expertise in sales, negotiations, business development, and project management.</p> <p>She is Currently working for a mandate firm – Stratton Realty, LLP and heading leading commercial real estate sales as Project Head – Sales at Kushal Wallstreet.</p> <p>Experienced in driving revenue growth, closing high-value deals, and managing key client relationships. A qualified Company Secretary with a strong legal and compliance background.</p>
Disclosure of relationship between directors	Not Applicable
Information as required pursuant to BSE circular with ref No. LIST/COMP/14 018-19 and the National Stock Exchange of India Limited with ref. no. NSE/CML/2018/24, dated 20 th June 2018.	Mr. Payal Jain is not debarred from holding the office of director by virtue of any SEBI order or any other such activity.

NATH SEEDS

हर बीज खरा, शक्ति भरा

■ Nath House, Nath Road, Aurangabad - 431005 (MS) Tel : 0240-2376314/5/6/7
Email : info@nathseeds.com www.nathbiogenes.com

■ 1, Chateau Windsor, 86 Veer Nariman Road, Mumbai - 400020 (MS) Tel : 022-22871001, 22875653/4/5

NATH
GROUP